<DOC>
	<DOCNO>NCT01164826</DOCNO>
	<brief_summary>The purpose study : - To Assess bioequivalence study Nabumetone 750 mg tablet Relafen® 750 mg tablet healthy , adult , human subject feed condition washout period 16 day . - To monitor adverse event ensure safety subject .</brief_summary>
	<brief_title>Bioequivalence Study Nabumetone 750 mg Tablets Dr. Reddy 's Under Fed Conditions</brief_title>
	<detailed_description>A randomized , open label , two treatment , two period , two sequence , single dose crossover , bioequivalence study nabumetone 750 mg tablet Dr. Reddy 's Laboratories Limited Relafen® 750 mg tablet Glaxosmithkline research triangle park , healthy , adult , human subject feed condition .</detailed_description>
	<mesh_term>Nabumetone</mesh_term>
	<criteria>Subjects must fulfill follow criterion consider inclusion study : Subjects provide write informed consent Subjects must healthy human being within 1845 year age ( inclusive ) weigh least 50 kg . Having Body Mass Index ( BMI ) 18.5 24.9 ( inclusive ) , calculate weight Kg/height m2 Subjects must normal health , determine medical history physical examination perform within 21 day prior commencement study . Subjects whose screen laboratory value within normal limit consider physician/investigator clinical significance . Have normal ECG , Xray vital sign . Availability subject entire study period willingness adhere protocol requirement evidence write informed consent . The subject exclude base follow criterion : Subjects incapable understanding informed consent . Subjects : 1 . Systolic blood pressure le 90 mm Hg 140 mm Hg 2 . Diastolic blood pressure le 60 mm Hg 94 mm Hg . Minor deviation ( 24 mm Hg ) checkin may acceptable discretion physician/investigator . 3 . Pulse rate SO/min lOO/min . History hypersensitivity idiosyncratic reaction Nabumetone relate drug . Any evidence impairment renal , hepatic , cardiac , lung gastrointestinal function . Clinically significant illness within 4 week start study . Consumption grapefruit past ten day prior dose day completion study . Regular smoker habit smoke nine cigarette per day difficulty abstain smoke 48 hour dose completion study . Subjects take counter prescribed medication last7 day date study . Subjects take enzyme modify drug systemic medication within past 30 day prior start clinical study History psychiatric illness , may impair ability provide write , informed consent . Subjects clinically significant abnormal value laboratory parameter . Subjects participate clinical investigation use experimental drug bleed 330 rnL past 90 day date start study . Subjects positive screen drug abuse alcohol . Any subject Nabumetone contraindicate medical reason . Any subject recent history surgery . A history difficulty donate blood . A positive hepatitis screen include hepatitis B surface antigen , anti HCV Anti HAV antibodies A positive test result HIV antibody and/or syphilis A recent history presence asthma ( include aspirin induce asthma ) nasa polyp . A recent history alcoholism &lt; 2 year ) moderate ( 180 mL/day ) alcohol use , consumption alcohol within 48 hr prior receive Investigational Product . An unusual diet , whatever reason ( e.g . lowsodium ) , four week prior receive Investigational Product throughout subject participation study . In case subject selection discretion Investigator / Medical expert . Female subject pregnant able ( woman child bear potential ) become pregnant study allow participate .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>Bioequivalence</keyword>
	<keyword>Crossover</keyword>
	<keyword>Nabumetone</keyword>
</DOC>